11:25 AM EST, 11/17/2025 (MT Newswires) -- (Corrected to add "billion" in headline.)

Johnson & Johnson ( JNJ ) has agreed to buy Halda Therapeutics for $3.05 billion in cash as the healthcare products conglomerate aims to expand its portfolio of therapies for solid tumors, including prostate cancer.

The deal, which requires antitrust clearance, is anticipated to complete within the next few months, the companies said Monday in separate statements.

Halda's proprietary platform develops therapies for solid tumors, while the company's lead candidate is HLD-0915, a prostrate cancer treatment candidate.

"Results seen with HLD-0915 demonstrate impressive preliminary efficacy and a strong early safety profile in prostate cancer," said John Reed, executive vice president, innovative medicine, research and development, at Johnson & Johnson ( JNJ ). "We are eager to accelerate the ongoing phase 1/2 clinical trial of HLD-0915 and progress a pipeline of novel product candidates based on (Halda's proprietary platform) technology."

The deal includes Halda's earlier therapy candidates for breast, lung and other tumors, Johnson & Johnson ( JNJ ) said.

"This acquisition further strengthens our deep oncology pipeline with an exciting lead asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncology, providing a potential mid- and long-term catalyst for growth," said Jennifer Taubert, worldwide chairman of innovative medicine at Johnson & Johnson.

Johnson & Johnson said it anticipates a $0.15 impact on adjusted earnings per share next year from financing and equity awards for Halda employees upon closing.

"Through this transaction, we will continue to rapidly develop this promising program for patients with prostate cancer and advance Halda's innovative pipeline from its (Regulated Induced Proximity TArgeting Chimera) platform to address a range of diseases," Halda Chief Executive Christian Schade said.

Price: 198.78, Change: +2.85, Percent Change: +1.45